Risk Assessment of Drug Interaction Potential and Concomitant Dosing Pattern on Targeted Toxicities in Pediatric Cancer Patients

Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 3

Abstract

This investigation evaluated the impact of potential drug interactions on the incidence of reported toxicities seen with common dosing patterns in children with cancer, with the intent of being able to screen and reduce the incidence of adverse drug reactions (ADRs) in the future. Toxicity reported in pediatric cancer patients treated at the Children’s Hospital of Philadelphia from 2004 to 2010 were abstracted from a cancer tumor registry and merged with drug order profiles from the medical record system. Analysis datasets were created in SAS and permutation algorithms were used to identify pairwise drug combinations associated with specific toxicity occurrence. Relative risk of toxicity based on dosing pattern was assessed via comparison to control patients. A total of 326 of 1,713 patients (19%) had reportable toxicities. Neutrophil count decreases and alanine aminotransferase increases represented the highest occurring, corresponding to 28.8% and 31.9% prevalence among patients reporting toxicity, respectively. Of coadministered drug pairs, acetaminophen–diphenhydramine occurred most frequently; however, methotrexate–vincristine was the highest occurring pair linked to a single toxicity (hepatotoxicity). Toxicity was highly associated with the diagnoses of leukemia (52.1%) or neuroblastoma (28.5%). Comparison of the dosing interval (≤30 versus >30 min) suggested that risk of toxicity can be associated with the timing of coadministration, with ≤30 min increasing the risk of hepatotoxicity with fentanyl–midazolam and methotrexate–midazolam combinations. Knowledge of drug interactions in children with cancer may help reduce the incidence of ADRs by providing pharmacotherapy options that may reduce the likelihood of toxicity.

Authors and Affiliations

Jeffrey S. Barrett, Dimple Patel, Erin Dombrowsky, Gaurav Bajaj, Jeffrey M. Skolnik

Keywords

Related Articles

Lipidic Systems for In Vivo siRNA Delivery

The ability of small-interfering RNA (siRNA) to silence specific target genes not only offers a tool to study gene function but also represents a novel approach for the treatment of various human diseases. Its clinical u...

Effect of Traumatic Brain Injury, Erythropoietin, and Anakinra on Hepatic Metabolizing Enzymes and Transporters in an Experimental Rat Model

The online version of this article (doi:10.1208/s12248-015-9792-y) contains supplementary material, which is available to authorized users.

R4 Regulator of G Protein Signaling (RGS) Proteins in Inflammation and Immunity

G protein-coupled receptors (GPCRs) have important functions in both innate and adaptive immunity, with the capacity to bridge interactions between the two arms of the host responses to pathogens through direct recogniti...

Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial

The online version of this article (doi:10.1208/s12248-014-9631-6) contains supplementary material, which is available to authorized users.

Download PDF file
  • EP ID EP681135
  • DOI  10.1208/s12248-013-9489-z
  • Views 74
  • Downloads 0

How To Cite

Jeffrey S. Barrett, Dimple Patel, Erin Dombrowsky, Gaurav Bajaj, Jeffrey M. Skolnik (2013). Risk Assessment of Drug Interaction Potential and Concomitant Dosing Pattern on Targeted Toxicities in Pediatric Cancer Patients. The AAPS Journal, 15(3), -. https://europub.co.uk./articles/-A-681135